貨號：GS40019

Alirocumab is a fully human monoclonal antibody (IgG1) designed as a PCSK9 inhibitor for the treatment of hypercholesterolemia. It functions by binding to and inhibiting circulating proprotein convertase subtilisin/kexin type 9, thereby preventing the degradation of hepatic LDL receptors. This leads to a sustained and significant reduction in low-density lipoprotein cholesterol levels. It is administered via subcutaneous injection and is approved for use in patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) who require additional LDL-C lowering despite maximally tolerated statin therapy, helping to reduce the risk of heart attack and stroke.